Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. - Wikidata - awgldk - TriplyDB

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

http://www.wikidata.org/entity/Q42613543

about

Protein substitute for children and adults with phenylketonuria Protein substitute for children and adults with phenylketonuria Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria Nutritional Management of Phenylketonuria Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids Phenylketonuria: a review of current and future treatments New Strategies for the Treatment of Phenylketonuria (PKU)Phenylketonuria: translating research into novel therapies Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice Novel pharmacological chaperones that correct phenylketonuria in mice.Large neutral amino acids in the treatment of PKU: from theory to practice.Phenylalanine hydroxylase misfolding and pharmacological chaperones.Up to date knowledge on different treatment strategies for phenylketonuria.Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.Phenylketonuria: nutritional advances and challenges Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria Nutritional management of PKU with glycomacropeptide from cheese whey.Progress toward cell-directed therapy for phenylketonuria.Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria.Clinical therapeutics for phenylketonuria.Protein substitutes for phenylketonuria in Europe: access and nutritional composition.Clinical utility gene card for: Phenylketonuria.Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites.The complete European guidelines on phenylketonuria: diagnosis and treatment.Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys.Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.Dietary intervention in the management of phenylketonuria: current perspectives.Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels.

P2860

Q24187935-48BBB400-879C-4CF6-A5B5-80CF9D1F4ABE Q24241445-25DD0ADA-B757-4670-BC61-06CE16848351 Q24606705-6CF0BF77-CC08-4EEE-8298-89937A13386B Q24613843-F9E03133-31AD-4D85-9FCA-319A64EB42E4 Q24645084-4F7C553C-C167-4EC3-8241-26673B14ED5A Q26770291-0F726794-B473-4755-B6B9-E379D3A44E04 Q26999278-0836508D-D2CE-46EB-8B17-180259357C46 Q27015749-8214FE16-D1FA-4BAF-A6AD-12F1F6356A4A Q28551217-EF08BC9F-DE07-48C3-AA65-BC4690805BDA Q34127906-3E6DB33F-1267-41CC-8374-D616D94999EA Q34145811-B5348E86-6982-4CB5-BDD0-53F58E497DB1 Q34556955-8458238C-26A7-4F73-AD80-B16764A3F16D Q35623929-E0FE9456-386B-426E-877F-BF9FB04EF92B Q35889337-19FA6AB1-72C9-4B88-AD03-45FE6CCFE83F Q36092265-73E82F36-FEFD-4A93-B9DD-DF1121ECC30D Q36110718-636D1511-9FE9-4519-AA80-3AFB28691872 Q36786748-BD72E8EF-F997-4BA9-B674-4ADCB96C7D7B Q37170974-326B6D3E-B033-423B-8927-33A515E10802 Q37575323-899FFBD1-9372-4215-9597-13ACB9616954 Q38096351-FC305207-FDE3-4414-AB42-DE1F2AF3B048 Q38383086-09D63799-8E60-4807-9DB1-9652385BC0C1 Q39819235-6B6AD1A6-1AB6-4E01-B644-25440841C3FE Q40491970-D56178F8-64FE-43E0-84DE-62CC09DDD380 Q42172645-36EAF58A-6AB3-49BB-BEA5-48BF54EE8ED6 Q42376686-4680EB78-D6A1-4E92-B8CE-F807AAF501CD Q47281654-30DFC473-E328-4A25-B120-838F90618806 Q47559946-0CF6CF13-6474-4D65-9E22-76B988F80336 Q49500552-C730AA79-9D1E-4417-8B99-91D23FE851A7 Q55386185-1DD4EAFE-BFD5-495D-9D46-45ECFEC10C85

P2860

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

http://www.wikidata.org/entity/Q42613543

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Double blind placebo control t ...... effect on blood phenylalanine.

@en

Double blind placebo control t ...... effect on blood phenylalanine.

@nl

type

label

Double blind placebo control t ...... effect on blood phenylalanine.

@en

Double blind placebo control t ...... effect on blood phenylalanine.

@nl

prefLabel

Double blind placebo control t ...... effect on blood phenylalanine.

@en

Double blind placebo control t ...... effect on blood phenylalanine.

@nl

P1433

Q42613543-F56B6CB8-B9EC-4710-9AF3-78F6EE06D942

P1476

Q42613543-2B387AF1-ECAA-435E-AE19-E9EF6E1D2249

P2093

Q42613543-1C6ECF04-EBFA-4539-A40F-8AFEDA52F5B3

Q42613543-216A4C3E-6759-4E9E-BD04-C287B7CA3922

Q42613543-233EB5A3-8849-4366-AB6B-755586372A3E

Q42613543-3FB26517-DC2A-483D-BF17-BA0DDAE55604

Q42613543-4F331F57-5FEC-461B-BCE8-0EF2215E614B

Q42613543-67050ED5-409E-424F-8471-AB22CCB83B42

Q42613543-70482E99-6E2F-43F5-8EE2-C788228FB14C

Q42613543-957F1FA2-6E9A-4E2B-855D-19BC5A8BCD15

Q42613543-97F67764-C1AA-41C1-B2C1-C5CE5066EB91

Q42613543-B6D11A5F-84DC-4196-90A6-4C258F5FCE39

P2860

Q42613543-246FEA30-F945-487E-A6DF-2774F7AF24E7

P2888

Q42613543-C0B6367E-678D-4426-97F2-7855FFDF4A8B

P304

Q42613543-9F1D69B5-BD52-42F2-A8D3-153BCEB9CC0A

P31

Q42613543-948B09C6-1AC4-49E7-BDE9-40F9D4C7EBE7

P356

Q42613543-A500B21F-3E24-4EE7-AD33-546DB7B13152

P433

Q42613543-BBA67D80-D6E7-4B4B-9EBC-4B6BF4252688

P478

Q42613543-643AE31C-65B5-4E78-9BB0-3AD68203D08A

P577

Q42613543-214FEC74-498C-4088-8AA2-138D2CE43595

P6179

Q42613543-D371E3EC-F419-4F97-BE79-58EC7E15E734

P698

Q42613543-8B25E15A-9D1D-45F8-873F-65AC07AF3D4E

P921

Q42613543-88366AEB-6359-4A24-954B-5F0D2C35A916

P356

S10545-007-0556-4

P1433

Journal of Inherited Metabolic Disease

P1476

Double blind placebo control t ...... effect on blood phenylalanine.

@en

P2093

A B Burlina

http://www.w3.org/2001/XMLSchema#string

A P Burlina

http://www.w3.org/2001/XMLSchema#string

C Braga

http://www.w3.org/2001/XMLSchema#string

E Grechanina

http://www.w3.org/2001/XMLSchema#string

F Guttler

http://www.w3.org/2001/XMLSchema#string

G Bhatia

http://www.w3.org/2001/XMLSchema#string

J Grady

http://www.w3.org/2001/XMLSchema#string

K Michals-Matalon

http://www.w3.org/2001/XMLSchema#string

L Fiori

http://www.w3.org/2001/XMLSchema#string

M Giovannini

http://www.w3.org/2001/XMLSchema#string

P2860

Über Ausscheidung von Phenylbrenztraubensäure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillität

P2888

s10545-007-0556-4

P304

153-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10545-007-0556-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002736870

http://www.w3.org/2001/XMLSchema#string

P698

17334706

http://www.w3.org/2001/XMLSchema#string

P921